MAPK13

Across TCGA pan-cancer cohorts, MAPK13 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of MAPK13’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where MAPK13 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAPK13 is over-expressed in tumor, although a few such as KIRP and COAD show the opposite, repressed pattern.

THCA, BLCA, and LUAD are the cancer types where MAPK13 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAPK13 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	+0.972	<.001	11	view →
BLCA	All	All	+1.680	.002	8	view →
LUAD	Female	III,IV	+0.765	<.001	7	view →
LUSC	All	II,III,IV	+0.623	<.001	7	view →
UCEC	All	All	+1.784	<.001	6	view →
BRCA	All	III,IV	+1.119	<.001	6	view →
CHOL	Female	All	+4.743	<.001	5	view →
STAD	All	All	+1.121	.003	5	view →
LIHC	All	All	+0.730	.002	5	view →
KIRP	All	III,IV	−1.049	.011	3	view →
COAD	Female	IV	−0.455	.014	2	view →
PRAD	All	All	−0.344	.022	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

MAPK13–THCA

Open the THCA breakdown →